Abbott commercially rolls out Oncodetect MRD assay

Abbott has commercially launched its next-generation Oncodetect MRD assay, which identifies traces of cancer in patients with solid tumours. The Oncodetect MRD test utilises whole-genome sequencing to monitor circulating tumour DNA during and after therapy. Abbott estimates that over three million patients in the US with solid tumours could benefit from Oncodetect MRD test. Credit: Premreuthai / Shutterstock.com. Abbott has commercially launched its next-generation Oncodetect molecular residual disease (MRD) assay, a personalised blood test that identifies traces of cancer in patients with solid tumours. Available through healthcare providers, the tumour-informed diagnostic tool utilises whole-genome sequencing to monitor circulating tumour deoxyribonucleic…

Source: Medical Device Network